Monday, February 23, 2026

Creating liberating content

Choose your language

hello@global-herald.net

China building a different...

The headlines are predictable by now. The United States restricts chip exports....

Asia braces for Trump’s...

TOKYO — Asia has spent the few days since the Supreme Court...

Team USA defeats Canada...

The GIST: It wasn’t a Miracle, but 46 years later, the result...
HomePoliticsEuropeNovo Nordisk stock...

Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly


Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.



Source link

Get notified whenever we post something new!

spot_img

Create a website from scratch

Just drag and drop elements in a page to get started with Newspaper Theme.

Continue reading

China building a different AI future than the West

The headlines are predictable by now. The United States restricts chip exports. Chinese labs release competitive models. Pundits declare who is “winning” the artificial intelligence race. The language borrows from sport and war: sprints, breakthroughs and supremacy. It makes...

Asia braces for Trump’s tariff Plan B and dollar Plan C

TOKYO — Asia has spent the few days since the Supreme Court struck down Donald Trump’s tariffs bracing for what might come next from the most mercantilist White House in 125 years. On Friday, the court ruled against the...

Germany – Centre for Economic Strategy

Germany - Centre for Economic Strategy ...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.